en · de · es
faq-desk.peptides5388.com › Blog › Identity And Research Background — 2026 Update

Identity And Research Background — 2026 Update

By Editorial Desk · published 2026-05-29 · last reviewed 2026-06-21 · Blog

A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2026-06-21 and is reviewed periodically as new material appears.

Identity And Research Background

AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.

AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.

AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.

Research and Regulatory Context

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.

Aod-9604 at a glance

PropertyValueNotes
Molecular classSynthetic peptideFragment analog of human growth hormone
Sequence basishGH 176–191 regionModified C-terminal fragment
Common synonymsAOD-9604; AOD9604; hGH fragmentResearch and trade names vary
Regulatory statusNot approved as a drugProhibited in competitive sport
Research codeAOD9604Used in scientific and patent literature

Identity and Research Origin

AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Related pages on this site

Background And Research Context

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.

The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.

In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.

Background from the literature

The fungus is highly toxic, and is responsible for the majority of fatal mushroom poisonings worldwide. Its biochemistry has been researched intensively for decades, and 30 grams (1.1 ounces), or half a cap, of this mushroom is estimated to be enough to kill a human. On average, one person dies a year in North America from death cap ingestion. The toxins of the death cap mushrooms primarily target the liver, but other organs, such as the kidneys, are also affected. Symptoms of death cap mushroom toxicity usually occur 6 to 12 hours after ingestion. Symptoms of ingestion of the death cap mushroom may include nausea and vomiting, which is then followed by jaundice, seizures, and coma, which will lead to death. The mortality rate of ingestion of the death cap mushroom is believed to be around 10–30%. Some authorities strongly advise against putting suspected death caps in the same basket with fungi collected for the table and to avoid even touching them. Furthermore, the toxicity is not reduced by cooking, freezing, or drying. Poisoning incidents usually result from errors in identification. Recent cases highlight the issue of the similarity of A. phalloides to the edible paddy straw mushroom (Volvariella volvacea), with East and Southeast Asian immigrants in Australia and the West Coast of the U.S. falling victim. In an episode in Oregon, four members of a Korean family required liver transplants. Many North American incidents of death cap poisoning have occurred among Laotian and Hmong immigrants, since it is easily confused with A.

An especially strong Walker circulation causes La Niña, which is considered to be the cold oceanic and positive atmospheric phase of the broader El Niño–Southern Oscillation (ENSO) weather phenomenon, as well as the opposite of El Niño weather pattern, where sea surface temperature across the eastern equatorial part of the central Pacific Ocean will be lower than normal by 3–5 °C (5.4–9 °F). The phenomenon occurs as strong winds blow warm water at the ocean's surface away from South America, across the Pacific Ocean towards Indonesia. As this warm water moves west, cold water from the deep sea rises to the surface near South America. The movement of so much heat across a quarter of the planet, and particularly in the form of temperature at the ocean surface, can have a significant effect on weather across the entire planet. Tropical instability waves visible on sea surface temperature maps, showing a tongue of colder water, are often present during neutral or La Niña conditions. La Niña is a complex weather pattern that occurs every few years, often persisting for longer than five months. El Niño and La Niña can be indicators of weather changes across the globe. Atlantic and Pacific hurricanes can have different characteristics due to lower or higher wind shear and cooler or warmer sea surface temperatures.

The first generation uses linking technologies that conjugate drugs non-selectively to cysteine or lysine residues in the antibody, resulting in a heterogeneous mixture. This approach leads to suboptimal safety and efficacy and complicates optimization of the biological, physical and pharmacological properties. Site-specific incorporation of unnatural amino acids generates a site for controlled and stable attachment. This enables the production of homogeneous ADCs with the antibody precisely linked to the drug and controlled ratios of antibody to drug, allowing the selection of a best-in-class ADC. An Escherichia coli-based open cell-free synthesis (OCFS) allows the synthesis of proteins containing site-specifically incorporated non-natural amino acids and has been optimized for predictable high-yield protein synthesis and folding. The absence of a cell wall allows the addition of non-natural factors to the system to manipulate transcription, translation and folding to provide precise protein expression modulation.

Several artificial nucleobases have been synthesized, and successfully incorporated in the eight-base DNA analogue named Hachimoji DNA. Dubbed S, B, P, and Z, these artificial bases are capable of bonding with each other in a predictable way (S–B and P–Z), maintain the double helix structure of DNA, and be transcribed to RNA. Their existence could be seen as an indication that there is nothing special about the four natural nucleobases that evolved on Earth. On the other hand, DNA is tightly related to RNA which does not only act as a transcript of DNA but also performs as molecular machines many tasks in cells. For this purpose it has to fold into a structure. It has been shown that to allow to create all possible structures at least four bases are required for the corresponding RNA, while a higher number is also possible but this would be against the natural principle of least effort.

Sources: en.wikipedia.org

Reference notes

Considering that stress-response proteins (like Hsp70) evolved before apoptotic machinery, Hsp70's direct role in inhibiting apoptosis provides an interesting evolutionary picture of how more recent (apoptotic) machinery accommodated previous machinery (Hsps), thus aligning the improved integrity of a cell's proteins with the improved chances of that particular cell's survival. In mice, exogenous recombinant human Hsp70 (eHsp70), delivered intranasally, increases lifespan. Although the maximum lifespan increased only moderately, the overall mortality rate in treated animals was much lower compared with the control group. Also this eHsp70-treatment improves learning and memory of mice in old age, increases their curiosity.

The Southern Rhodesian government encouraged private enterprise to form secondary industries to exploit the colony's natural resources and increase production, but also set up some state industries in an attempt to spark growth. The establishment of the RATG prompted a minor economic boom, and also caused the primary direct demand placed on Southern Rhodesia's black population during the early stages of the war—a programme of conscripted labour to build the aerodromes. The government assigned labour quotas for each district to native commissioners across the territory who in turn called on local chiefs and headmen to provide workers. The tribal leaders decided who was required at the kraal and who would report to the district native commissioner for work. This system, known locally as the chibaro, cibbalo, isibalo or chipara—according to Charles van Onselen, synonymous etymologically with concepts ranging from contract labour to slavery—had been relatively widespread during Company rule (1890–1923), but had fallen out of use by the 1930s. Some tribal communities were resettled to make room for the airstrips. The chibaro workers received pay and provisions, but the salary of 15s/- per month compared unfavourably with the 17s/6d generally received on white-owned farms. It met with widespread opposition, with many men electing to run away rather than join the work parties. "Hundreds if not thousands", according to Kenneth Vickery, crossed into Bechuanaland or South Africa to avoid the call-up.

=== Shotguns === Browning Auto-5 - Formally adopted in November 1965, used in tropical conditions and for explosive ordnance disposal work Remington 870 - Special forces issue. Also used to a limited degree in tropical conditions.

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 the same as human growth hormone?

No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.

Was AOD-9604 approved for weight loss?

It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.

Why is AOD-9604 banned in sports?

WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.

Is AOD-9604 approved for medical use?

No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.

Network